These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company operates through three segments: Enzo Life Sciences, Enzo Clinical Labs and Enzo Therapeutics. Enzo Life Sciences segment manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers around the world. Enzo Clinical Labs segment provides diagnostic services to the healthcare community. Enzo Therapeutics segment conducts research and development activities for therapeutic drug candidates.
Type
Public
HQ
New York, US
Founded
1976
Size (employees)
433 (est)
Website
enzo.com
Enzo Biochem was founded in 1976 and is headquartered in New York, US
Report incorrect company information

Enzo Biochem Office Locations

Enzo Biochem has an office in New York
New York, US (HQ)
527 Madison Ave
Show all (1)
Report incorrect company information

Enzo Biochem Financials and Metrics

Enzo Biochem Financials

Enzo Biochem's revenue was reported to be $102.77 m in FY, 2016 which is a 5.3% increase from the previous period.
USD

Revenue (Q3, 2018)

80.3 m

Gross profit (Q3, 2018)

45.5 m

Gross profit margin (Q3, 2018), %

56.7%

Net income (Q3, 2018)

(4.6 m)

EBIT (Q3, 2018)

(6.5 m)

Market capitalization (14-Jun-2018)

275.9 m

Closing share price (14-Jun-2018)

5.9

Cash (30-Apr-2018)

62.6 m
Enzo Biochem's current market capitalization is $275.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

93.7 m95.9 m97.6 m102.8 m

Revenue growth, %

2%2%5%

R&D expense

3.5 m

Operating expense total

3.5 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

24.1 m22.9 m24 m24.8 m23.1 m24 m25.2 m24.6 m26.4 m26.3 m26.3 m27.1 m27.7 m54.6 m80.3 m

Cost of goods sold

34.8 m

Gross profit

45.5 m

Gross profit Margin, %

57%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9 m17.5 m18.1 m67.8 m

Accounts Receivable

12.3 m12.5 m6.7 m6.7 m

Inventories

8.8 m8.7 m7.4 m7 m

Current Assets

32.6 m40.7 m46.5 m91.4 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

7.4 m7.6 m14.8 m16.6 m15.3 m14.4 m30.6 m37 m32.4 m67.2 m62.4 m62.6 m66.8 m64.5 m62.6 m

Accounts Receivable

6.7 m6.7 m

Inventories

9.1 m9.2 m9 m8.5 m8.3 m8 m7.6 m7.4 m7 m7.2 m7.1 m7.2 m7.2 m7.5 m7.3 m

Current Assets

32.4 m30.6 m38.2 m39.7 m37 m36.1 m52.8 m59.2 m55.2 m90.4 m86.9 m87.5 m91 m89.5 m86.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.2 m)(10 m)(2.3 m)45.3 m

Inventories

60 k159 k1.2 m466 k

Cash From Operating Activities

(10 m)(1.7 m)(3.7 m)53.1 m

Cash From Investing Activities

(971 k)(833 k)(1.8 m)(1.5 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(2.8 m)(6.4 m)(6.8 m)(3.7 m)(7.8 m)(10.7 m)4.4 m11.3 m9.2 m(1.5 m)(2.5 m)(2.6 m)(640 k)(1.5 m)(4.6 m)

Inventories

(252 k)(381 k)(144 k)107 k306 k597 k(210 k)(20 k)447 k(298 k)(238 k)(213 k)(198 k)(430 k)(257 k)

Cash From Operating Activities

(3.3 m)(4.7 m)(2.7 m)(2.8 m)(6.5 m)(8.2 m)13.2 m20.1 m17 m(333 k)(2.8 m)(1.9 m)2.6 m835 k(475 k)

Cash From Investing Activities

(314 k)(472 k)(524 k)(259 k)(653 k)(1.2 m)(490 k)(941 k)(1.4 m)(514 k)(687 k)(1.4 m)(461 k)(1.1 m)(1.7 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics

Enzo Biochem Operating Metrics

FY, 2016

Facilities

2

Patents Issued

314

Patents Pending

146
Show all operating metrics

Enzo Biochem Revenue Breakdown

Embed Graph

Enzo Biochem revenue breakdown by business segment: 69.0% from Clinical Labs and 31.0% from Life Sciences

Report incorrect company information

Enzo Biochem News and Updates

Report incorrect company information